This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Haemonetics Completes $255 Million Acquisition of OpSens MT
OpSens Brief: NYSE's Haemonetics Completed Acquisition MT
Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS). CI
OpSens Receives Final Order For Its Acquisition By NYSE's Haemonetics MT
OpSens Brief: Says Received Final Order For Its Acquisition By NYSE's Haemonetics MT
Opsens Shareholders Approve Arrangement With Haemonetics MT
Transcript : Opsens Inc. - Shareholder/Analyst Call
OpSens Brief: In connection with prior announced acquisition by Haemonetics Obtained Regulatory Clearance of Arrangement in the US and Canada; Regulatory Approvals Condition Satisfied MT
Opsens Inc. Reports Earnings Results for the Full Year Ended August 31, 2023 CI
OpSens Fiscal Q4 Loss Narrows as Sales Rise 57% Ahead of Acquisition by Haemonetics MT
Opsens Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023 CI
OpSens Brief: ISS Recommends Shareholders Vote For Opsens Inc. Plan of Arrangement with NYSE's Haemonetics MT
Barrington Research's Initial Take on Haemonetics' Acquisition of OpSens MT
Needham on Opsens Being Acquired by Haemonetics MT
Toronto Stocks Advance; Opsens Soars on C$345 Million Buyout Deal DJ
OpSens Signed Definitive Agreement For Its Acquisition By NYSE's Haemonetics MT
Haemonetics to Acquire OpSens for $253 Million in Cash MT
OpSens Brief: Signed Definitive Agreement For Its Acquisition By NYSE's Haemonetics MT
Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million. CI
Transcript : Opsens Inc., Q3 2023 Earnings Call, Jul 13, 2023
Opsens Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023 CI
OpSens Reports Q3 Consolidated Revenue of $13.2 Million; Net Loss of $0.04 Per Diluted Share MT
OpSens Brief: Q3 Consolidated revenues of $13.2 million, compared with $10.1 million in the third quarter of 2022 MT
North American Morning Briefing : Optimism Set to Continue as Focus Shifts to Earnings DJ
OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR Study CI
Chart Opsens Inc.
More charts
OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.
More about the company
  1. Stock Market
  2. Equities
  3. OPS Stock
  4. News Opsens Inc.
  5. OpSens Announcing Submission To U.S. FDA For New Guidewire For TAVR Procedure